Day: March 11, 2024

SOMERSET, N.J., March 11, 2024 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced its participation in the HIMSS Global Health Conference and Exhibition, taking place from March 11-15 in Orlando, Florida. Positioned at booth 5281, CareCloud will use this opportunity to showcase its state-of-the-art generative AI solutions, alongside its other products and services for physician practices. HIMSS is expected to draw over 40,000 healthcare professionals from various sectors of the health ecosystem and will focus on innovation in the areas of digital health transformation, applied artificial intelligence, cybersecurity, emerging technologies, patient safety and quality, among others. The exhibit floor will...

Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release financial results for the fourth quarter ended December 31, 2023 on Monday, March 18th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and referencing conference ID 13744365. To access the Call me™ feature, which avoids having to wait for an operator, click here. A live webcast of the conference call will also be available here and on the investor relations page...

HPV-related Tissue-Sample Mimics for QC of histology and PCR analyses MISSISSAUGA, Ontario, March 11, 2024 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of Quality Assessment Products (“QAPs™”) for supporting the quality control (“QC”) of histology and PCR-based tests driven by tissue-samples of Head and Neck cancer caused by human papilloma virus (“HPV”). Its results presentation will be made at EUROGIN 2024, an international collaborative conference and exhibition focused upon innovations in HPV research and global cancer solutions taking place in Stockholm, Sweden from March 13 to 16, 2024. While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer...

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”) today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company for portfolio expansion, enhanced development capabilities, and growth of a robust intellectual property portfolio. The laboratory space in Cambridge sits within 150 acres and two million square feet of high technology and laboratory buildings, housing nearly 7,000 people at over 130 companies that range from exciting start-ups to some of the world’s leading technology and life science...

FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for the Full 36-months for ASCENIV and BIVIGAM Provides for Improved Inventory Management and Ease of Product Administration to Patients Approval of Extended Ambient Storage Conditions for ASCENIV & BIVIGAM is Immediately Effective and Now Commercially Available to U.S. Healthcare Providers RAMSEY, N.J. and BOCA RATON, Fla., March 11, 2024 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the United States Food and Drug Administration’s (“FDA”) approval for its supplemental...

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen. “We are excited to welcome him to FibroGen during this critical time as we prepare for two pivotal read-outs for pamrevlumab in pancreatic cancer, advance Phase 2 planning...

VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson’s disease and obesity in H2 2024 Topline Phase 2 data for VTX2735 in CAPS patients establish clinical proof of concept; Ventyx is planning to evaluate VTX2735 in cardiovascular diseases Early Phase 2 open-label extension data continue to support the clinical profile of VTX002 in ulcerative colitis; Ventyx is planning to seek a partner or other nondilutive financing for pivotal Phase 3 trial Based on pipeline reprioritization and recent PIPE financing, Ventyx expects its current cash, cash equivalents and marketable securities to fund planned operations into at least H2 2026 SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”),...

TORONTO, March 11, 2024 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. My fellow Shareholders, As Lifeist prepares for a truly transformative year, we have received meaningful feedback from shareholders regarding the strategic focus of Lifeist going forward, its compensation structure and incentivization of management, and the value that fresh insights and approaches might bring to Lifeist’s core businesses. At this time, Meni Morim wishes to announce his intent to step down as CEO of Lifeist after the Board of Directors, led by Mr. Branden Spikes, has completed its executive search and appointed a new CEO to assume leadership of Lifeist. Until a new CEO has been selected, Mr. Morim has agreed to remain and will continue to serve as CEO, at reduced compensation, to keep the operating subsidiaries on track through the strategic...

Figure 1Location and trace of LR167 and LR168 (results pending) within the Romanera drill program.Figure 2La Romanera Longitudinal Section showing the location of drill hole LR167 pierce point.TORONTO, March 11, 2024 (GLOBE NEWSWIRE) — Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) is pleased to announce additional assay results from the ongoing drilling program at La Romanera deposit, part of Emerita’s wholly owned Iberian Belt West project (“IBW” or the “Project”).  IBW hosts three previously identified massive sulphide deposits: La Infanta, La Romanera and El Cura. Results contained in this release are from La Romanera. All deposits are open for expansion. Assays have been received for diamond drill hole LR167 (Fig. 1). The hole was one of a pair designed to better...

MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1β and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially applicable across a range of inflammatory disorders, metabolic disorders, as well as ocular and neurological diseases IND-enabling studies ongoing; IND submission anticipated in Q1 2025 BOSTON, March 11, 2024 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced a novel development candidate, MRT-8102, a potent, highly selective and orally bioavailable NIMA related kinase 7 (NEK7)-directed MGD. MRT-8102 is expected to be developed for the treatment of inflammatory diseases driven by interleukin-1β (IL-1β) and...